Please login to the form below

Beta thalassemia

This page shows the latest Beta thalassemia news and features for those working in and with pharma, biotech and healthcare.

Meanwhile Bluebird is proposing a similar five-year instalment plan for its 1.57m beta thalassemia therapy Zynteglo.

Bluebird puts €1.57m price on gene therapy Zynteglo

US biotech pioneering outcomes-based payment in Europe. Bluebird Bio’s gene therapy treatment for beta thalassemia Zynteglo is to be priced at 1.575m ($1.76m) in Europe, where the ... As the therapy is only currently licensed for use in beta
A first for Bluebird and Europe as gene therapy Zynteglo approved

That’s because Bluebird believes it can offer a compelling cost-effectiveness case for its treatment in beta thalassemia and sickle cell cases versus conventional stem cell treatment. ... beta thalassemia patients live in these four count.
Novartis secures US approval - and payers’ blessing – for $2m gene therapy Zolgensma

Another gene therapy pioneer, with a similar payment model looks likely to beat Novartis to the European market, however - Bluebird Bio and its beta thalassemia treatment.
Europe responding to gene therapy challenge, but picture remains fragmented

its gene therapies, starting with its soon-to-be-approved beta thalassemia therapy Zynteglo.
Post-merger Celgene to lead pharma growth

Celgene also has five potential blockbusters in its late-stage pipeline, including MS treatment ozanimod and myelodysplastic syndromes/beta thalassemia candidate luspatercept, which have both recently been filed.

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

The trials and tribulations of rare opportunities

Revenue projection in the year 2025 is $1.259bn,” he continued. Ringheim cited Celgene’s beta thalassemia candidate Sotatercept, which is expected to achieve sales of $458m by 2023, as a
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

LentiGlobin (betibeglogene darolentivec), an Orphan Drug and Breakthrough Therapy from Bluebird Bio, corrects the defect causing beta thalassemia, a blood disorder that causes life-threatening anaemia. ... The initial studies for LentiGlobin in
Bluebird: on a mission to ‘recode’ the DNA of healthcare

Bluebird Bio is just weeks away from gaining its first ever approval for its first ever product, Zynteglo, a groundbreaking gene therapy treatment for beta thalassemia. ... Increasingly factored into this equation is competition from companies following
Vertex: a vision of treating all CF patients worldwide draws closer

with sickle cell disease or beta thalassemia with FDA Fast Track Designation.
2019: CRISPR and therapeutic gene editing comes of age

beta thalassemia – to become the first CRISPR drug to start testing in Europe. ... The FDA placed the CTX001 programmed in beta thalassemia and a planned trial in sickle cell disease on a clinical hold shortly afterwards, but relaxed that last October.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Add my company

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Five key trends in precision and personalised healthcare: Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications: Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word: ...